Last reviewed 2026-05-24 · How we verify

varicella-6

Beijing Center for Disease Control and Prevention · FDA-approved active Biologic ✓ Verified May 2026

varicella-6 is a Live attenuated vaccine Biologic drug developed by Beijing Center for Disease Control and Prevention. It is currently FDA-approved for Prevention of varicella (chickenpox) in susceptible individuals.

Varicella-6 is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent varicella (chickenpox) infection.

Varicella-6 is a vaccine used to prevent varicella, a viral infection that causes chickenpox. It is studied in clinical trials, such as NCT01866566, for its safety and immunogenicity after two doses of vaccination.

At a glance

Generic name	varicella-6
Sponsor	Beijing Center for Disease Control and Prevention
Drug class	Live attenuated vaccine
Target	Varicella-zoster virus
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The vaccine contains a weakened strain of varicella-zoster virus that replicates in host cells but does not cause disease in immunocompetent individuals. This triggers both cellular and humoral immune responses, generating antibodies and T-cell memory that protect against subsequent natural infection with wild-type varicella-zoster virus.

Approved indications

Prevention of varicella (chickenpox) in susceptible individuals

Common side effects

Injection site reactions (erythema, swelling, pain)
Fever
Rash
Myalgia

Key clinical trials

The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

varicella-6 CI brief — competitive landscape report
varicella-6 updates RSS · CI watch RSS
Beijing Center for Disease Control and Prevention portfolio CI

Frequently asked questions about varicella-6

What is varicella-6?

varicella-6 is a Live attenuated vaccine drug developed by Beijing Center for Disease Control and Prevention, indicated for Prevention of varicella (chickenpox) in susceptible individuals.

How does varicella-6 work?

Varicella-6 is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent varicella (chickenpox) infection.

What is varicella-6 used for?

varicella-6 is indicated for Prevention of varicella (chickenpox) in susceptible individuals.

Who makes varicella-6?

varicella-6 is developed and marketed by Beijing Center for Disease Control and Prevention (see full Beijing Center for Disease Control and Prevention pipeline at /company/beijing-center-for-disease-control-and-prevention).

What drug class is varicella-6 in?

varicella-6 belongs to the Live attenuated vaccine class. See all Live attenuated vaccine drugs at /class/live-attenuated-vaccine.

What development phase is varicella-6 in?

varicella-6 is FDA-approved (marketed).

What are the side effects of varicella-6?

Common side effects of varicella-6 include Injection site reactions (erythema, swelling, pain), Fever, Rash, Myalgia.

What does varicella-6 target?

varicella-6 targets Varicella-zoster virus and is a Live attenuated vaccine.

Drug class: All Live attenuated vaccine drugs
Target: All drugs targeting Varicella-zoster virus
Manufacturer: Beijing Center for Disease Control and Prevention — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Prevention of varicella (chickenpox) in susceptible individuals

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing